Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

AmberHealth vs Ilant Health

AmberHealth
Graded #31

Higher grade

vs+26.10000000000001
Ilant Health
Graded #408

Lower grade

The verdict

AmberHealth takes it — 82.9/100 to 56.8/100.

AmberHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Round-$100 semaglutide nationwide, though tirzepatide runs $175 and it isn't verified.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAmberHealth +45
90
45
Dose & formulationAmberHealth +40
80
40
Clinical oversightIlant Health +4
79
83
Labs & monitoringAmberHealth +17
78
61
FulfillmentAmberHealth +24
86
62
Contract termsAmberHealth +27
82
55
AmberHealth · left barIlant Health · right bar

The numbers

MetricAmberHealthIlant Health
WeighScore82.9/10056.8/100
GradeB−C
Scorecard rank#31#408
Semaglutide$100/moNot disclosed
Tirzepatide$175/moNot disclosed
CoverageAll 50 statesCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
AmberHealth

Graded #31 · B−

Strengths

  • $100 semaglutide
  • All 50 states
  • Both molecules

Where it loses points

  • Not LegitScript-verified
  • Tirzepatide $175
  • Monitoring detail sparse
Ilant Health

Graded #408 · C

Strengths

  • Value-based, outcomes-driven obesity care model
  • Includes GLP-1 medications with transparent drug pricing for sponsors
  • Care team of board-certified obesity providers and behavioral specialists
  • Dietitians and peer navigators support adherence
  • Data-driven stratification targets the right interventions

Where it loses points

  • Distributed via employers and health plans, not direct cash-pay
  • Individuals generally cannot enroll without sponsor coverage
  • No public consumer pricing for GLP-1
  • Access gated behind organizational buyers
  • Not suited to consumers wanting direct-to-door GLP-1

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard